TuHURA Biosciences (HURA) Stock Price, News & Analysis

Company Overview

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states. This platform enables the identification of previously unrecognized biological pathways and target proteins, supporting both small‐molecule and biologic drug discovery. The technology is designed to accelerate early‐stage research by revealing disease drivers that traditional genomics and transcriptomics methods may overlook.

TuHURA is advancing a pipeline of programs in areas such as immunology, neurodegeneration and female health. The company has entered research collaborations with pharmaceutical and academic partners to validate targets and co‐develop lead candidates. These partnerships are helping TuHURA expand its reach into therapeutic areas of high unmet medical need while leveraging external expertise and resources.

Founded as a spin‐out from the University of California, Davis technology transfer office, TuHURA Biosciences is headquartered in California and serves a global research community. The company completed its initial public offering on the Nasdaq Capital Market under the ticker HURA in 2022, positioning itself for continued growth and innovation in proteomics‐driven drug discovery.

Key Stats

• Today's Range: $2.22 to $2.49
• 50-Day Range: $2.02 to $2.71
• 52-Week Range: $0.41 to $3.43
• Volume: 317,089 shs
• Average Volume: 235,478 shs
• Market Capitalization: $157.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

TuHURA Biosciences Stock Analysis - MarketRank™

TuHURA Biosciences scored higher than 39% of companies evaluated by MarketBeat, and ranked 681st out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TuHURA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

TuHURA Biosciences has a consensus price target of $9.00, representing about 264.4% upside from its current price of $2.47.

Amount of Analyst Coverage

TuHURA Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for TuHURA Biosciences are expected to decrease in the coming year, from ($0.56) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TuHURA Biosciences is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TuHURA Biosciences is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TuHURA Biosciences has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.88% of the float of TuHURA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

TuHURA Biosciences has a short interest ratio ("days to cover") of 31.85, which indicates bearish sentiment.

Change versus previous month

Short interest in TuHURA Biosciences has recently decreased by 2.11%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TuHURA Biosciences does not currently pay a dividend.

Dividend Growth

TuHURA Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.60

News Sentiment

TuHURA Biosciences has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for TuHURA Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 7 people have searched for HURA on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

MarketBeat Follows

3 people have added TuHURA Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TuHURA Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.06% of the stock of TuHURA Biosciences is held by insiders.

Percentage Held by Institutions

0.62% of the stock of TuHURA Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 8/15/2026
• AGM 2026: 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HURA
• Previous Symbol: NASDAQ:HURA
• CIK: 1498382
• Web: tuhurabio.com
• Phone: (813) 875-6600
• Fax: 604-608-5685
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TuHURA Biosciences: $9.00
• High Price Target: $10.00
• Low Price Target: $8.00
• Potential Upside/Downside: +264.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.05 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -156.12%
• Return on Assets: -105.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.34 per share
• Price / Book: 7.26

Miscellaneous

• Outstanding Shares: 63,680,000
• Free Float: 59,824,000
• Market Cap: $157.29 million
• Optionable: N/A
• Beta: -0.01